2026-10-13 12:33:00 UTC#452198newconfirmednews
IBIO stock news
IBIO stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire12 wire items
2026-10-09 07:20:08 UTC#436909updateconfirmednews
iBio, Inc. average analyst price target raised to $5.60 from $5.53, maintains Buy consensus
2026-10-08 04:20:06 UTC#429612newconfirmednews
iBio, Inc. average analyst price target lowered to $5.53 from $5.69, maintains Buy consensus
2026-09-21 11:28:15 UTC#341983newconfirmednews
iBio completes IBIO-600 Phase 1 enrollment, reports $88M cash runway; HC Wainwright initiates Buy rating
2026-09-17 10:24:00 UTC#326510newconfirmednews
iBio initiated at Buy with $7.00 price target by HC Wainwright & Co.
2026-09-17 10:23:51 UTC#326513duplicateconfirmednews
HC Wainwright initiates coverage of iBio with Buy rating and $7 price target
2026-09-14 20:23:01 UTC#309904newconfirmedpress release
iBio details pipeline milestones for obesity programs and confirms $88M cash runway through Q4 2028
2026-09-08 21:53:17 UTC#283904newconfirmednews
iBio's JADE101 shows strong Phase I results in IgA nephropathy, advancing to Phase II/III trials
2026-09-08 21:33:23 UTC#283819newconfirmednews
iBio advances long-acting antibody pipeline for obesity and muscle preservation toward clinical milestones
2026-08-28 12:45:03 UTC#235111duplicateconfirmednews
iBio, Inc. reports FY 2026 revenue of $100K and net loss of $33.04M
2026-08-28 12:12:47 UTC#234947newconfirmedpress release
iBio, Inc. reports fiscal year 2026 financial results and provides corporate update
2026-08-28 11:05:10 UTC#234639newconfirmednews